


EXHIBIT 32


Regulatory Affairs Update



RNA Leadership Team


**Nate Hartle, Sr. Director
Regulatory Affairs**

November 20th, 2015



**BUSINESS
CARE
CONNECTIVITY**


Addressing Rx Drug Abuse & Heroin Use



The Obama administration recently announced collective public and private sector efforts that focus on provider training, access to medication-assisted treatments and community awareness.

Sources: White House Memorandum for the Heads of Executive Departments & Agencies Re: Addressing Prescription Drug Abuse and Heroin Use, October 21, 2015; DEA National Drug Threat Assessment 2015

Our Program Design – A Regulatory View



Enhancements to Suspicious Order Reporting

Distributor Responsibility to Identify and Report Suspicious Orders:

“The registrant shall design and operate a system to disclose to the registrant suspicious orders of controlled substances...Suspicious orders include orders of unusual size, orders deviating substantially from a normal pattern, and orders of unusual frequency.”


- Enhance monthly thresholds with a robust statistical model
- Thresholds will adjust based on actual purchases
- ISMC pilot is in process
- Data analysis for chains and health systems is underway
- Implementation is expected throughout 2016

Model uses Actual Customer Purchase Data


M-1	M-2	M-3	M-4	M-5	M-6	M-7	M-8	M-9	M-10	M-11	M-12	M-13	M-14
Rolling 12 Months of Customer Specific Purchase History (i.e. Oxycodone Purchases)												Benchmark Group (Size) & New Thresholds Calculated	New Threshold Takes Effect
3 Months of Non-Contolled Purchase History Used to Calculate Size													

- Each month recent customer data is used to assess purchase history and pharmacy size, which both account for variability and growth.
- The proxy for size (benchmark group) is updated monthly.
- Thresholds reset monthly based on new purchasing data (one month lag).

Model calculates Threshold Options and allows for Due Diligence-based Thresholds



Benchmark Threshold Example



Due Diligence Threshold Example

Questionnaire

Questionnaire form with various fields and checkboxes. The form includes sections for company information, contact details, and compliance statements. It is titled 'Questionnaire' and has a header with 'McKesson' and 'Due Diligence'.

Site Visit/Call


Site Visit/Call form with various fields and checkboxes. The form includes sections for site information, visit details, and compliance statements. It is titled 'Site Visit/Call' and has a header with 'McKesson' and 'Due Diligence'.

TCR / Script & Dose Data

TCR / Script & Dose Data form with various fields and checkboxes. The form includes sections for TCR data, script data, and dose data. It is titled 'TCR / Script & Dose Data' and has a header with 'McKesson' and 'Due Diligence'.

Licensure & Registration

Licensure & Registration form with various fields and checkboxes. The form includes sections for licensure information, registration details, and compliance statements. It is titled 'Licensure & Registration' and has a header with 'McKesson' and 'Due Diligence'.



Text Code	Text Code	Text Code	Text Code	Text Code	Text Code
1	2	3	4	5	6
7	8	9	10	11	12
13	14	15	16	17	18
19	20	21	22	23	24
25	26	27	28	29	30
31	32	33	34	35	36
37	38	39	40	41	42
43	44	45	46	47	48
49	50	51	52	53	54
55	56	57	58	59	60
61	62	63	64	65	66
67	68	69	70	71	72
73	74	75	76	77	78
79	80	81	82	83	84
85	86	87	88	89	90
91	92	93	94	95	96
97	98	99	100	101	102

Next Steps

- Review of pilot results and analysis
- RNA data analysis has been completed and options reviewed
- AGI is re-calculating benchmark groupings
- Implementation plan and timeline will be modified and shared with PGORC/ORC
- Communication plans will be developed to support the rollout

Discussion

